Yonsei Med J.  2013 Jan;54(1):87-91. 10.3349/ymj.2013.54.1.87.

The Change of Prostate Cancer Treatment in Korea: 5 Year Analysis of a Single Institution

• Lee DH
• Jung HB
• Chung MS
• Lee SH
• Chung BH

• KMID: 1776922
• DOI: http://doi.org/10.3349/ymj.2013.54.1.87

Abstract

PURPOSE
We analyzed changes to the trends of prostate cancer management and patient characteristics at a single institute during 5 years due to the significant increase of the prostate cancer incidence and the robotic equipment in Korea.
MATERIALS AND METHODS
Prostate cancer patient data from a single institute recorded from 2006 to 2010 were analyzed. Cancer stage, initial treatment modalities, and the pattern of outpatient clinical management were reviewed.
RESULTS
Between 2006 and 2010, 386 prostate cancers were newly diagnosed at the institute. The proportion of localized and locally advanced cancer cases increased from 67% in 2006 to 79% in 2010 respectively. Among the treatment choices during follow-up in the out-patients clinic, the proportion of radical prostatectomies increased from 43% in 2006 to 62% in 2010. In contrast, the proportion of hormone therapies decreased from 58% to 37%. For initial treatment choice, radical prostatectomy was chosen for 59% of the patients who were newly diagnosed with cancer during the study period. However, hormone therapy alone was administrated as a primary therapy to 26%. Analysis of the radical prostatectomy subgroup showed that a robot-assisted technique was used in 83% of the patients, and the remaining 17% underwent an open radical prostatectomy.
CONCLUSION
As the prostate cancer incidence increased in Korea, the proportion of localized and locally advanced cancer also increased. In addition, the main treatment modality changed from non-surgical treatment to radical prostatectomy.

Keyword

Prostate cancer; radical prostatectomy; robotics; therapeutics

MeSH Terms

Databases, Factual
Follow-Up Studies
Hormones/*therapeutic use
Humans
Male
Prostatectomy/*methods/trends
Prostatic Neoplasms/*therapy
Republic of Korea
Robotics
Time Factors
Treatment Outcome
Hormones

Figure

• 

  Fig. 1 Increase in prostate cancer patients in the outpatient clinic between 2006 and 2010.

• 

  Fig. 2 Proportion of initial treatments between 2006 and 2010 according to pathologic stage (HT, hormone therapy; RT+HT, radiation therapy with hormone therapy; RRP, retropubic radical prostatectomy; RALP, robot-assisted laparoscopic radical prostatectomy; WW, watchful waiting). LAPC, locally advanced prostate cancer; LPC, localized prostate cancer; APC, advanced prostate cancer.

• 

  Fig. 3 Treatment trends in prostate cancer patients in the outpatient clinic between 2006 and 2010. HT, hormone therapy; RT, radiotherapy; OP, operation; WW, watchful waiting.

Reference

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999. 49:33–64. 1

2. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer. 2005. 41:834–845.

3. Statistics Korea. [http://kostat.go.kr/portal/english/index.action].

4. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010. 25:1113–1121.

5. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006. 66:1285–1291.

6. Dasgupta P, Kirby RS. The current status of robot-assisted radical prostatectomy. Asian J Androl. 2009. 11:90–93.

7. Sung ER, Jeong W, Park SY, Ham WS, Choi YD, Hong SJ, et al. The "halo effect" in Korea: change in practice patterns since the introduction of robot-assisted laparoscopic radical prostatectomy. J Robot Surg. 2009. 3:57–60.

8. National Evidence-based healthcare collaborating Agency (NECA), Korea. [http://www.neca.re.kr/eng].

9. Korea Ministry of Health and Welfare. National health insurance system. [http://english.mw.go.kr/front_eng/index.jSP].

10. Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006. 176(6 Pt 2):S47–S49.

11. Hamilton AS, Albertsen PC, Johnson TK, Hoffman R, Morrell D, Deapen D, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int. 2011. 107:576–584.

12. McVey GP, McPhail S, Fowler S, McIntosh G, Gillatt D, Parker CC. Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int. 2010. 106:1161–1164.

13. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci. 2006. 97:243–247.

14. Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol. 2007. 37:775–781.

15. National Comprehensive Cancer Network® (NCCN). NCCN clinical practice guidelines in oncology: Asia consensus statement: prostate cancer. [http://www.nccn.org/professionals/physician_gls/PDF/prostate-asia.pdf].

16. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010. 28:1117–1123.

17. Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996. 48:773–777.

18. Akaza H, Usami M, Hinotsu S, Ogawa O, Kagawa S, Kitamura T, et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol. 2004. 34:329–336.